The Food and Drug Administration yesterday alerted health care providers and the public to an increased risk of heart-related death from a drug used to treat gout, a type of arthritis in adults. Preliminary results from a safety clinical trial of the drug febuxostat (Uloric) show an increased risk of heart-related death compared to the gout medicine allopurinol, FDA said. “Health care professionals should consider this safety information when deciding whether to prescribe or continue patients on febuxostat,” the agency said. Febuxostat drug labels already carry a warning about cardiovascular events because the drug showed a higher rate of heart-related problems in clinical trials conducted before approval. “We are continuing to evaluate this safety issue and will update the public when we have more information,” FDA said. “We urge health care professionals and patients to report side effects involving febuxostat or other medicines to the FDA MedWatch program.”

Related News Articles

Blog
During National Nurses Week, Robyn Begley, AHA Senior Vice President and Chief Nursing Officer and CEO of AHA’s American Organization of Nurse Executives,…
Blog
In this AHA Stat blog post, Elisa Arespacochaga, vice president of the AHA Physician Alliance, highlights strategies from four female physicians who…
Headline
During National Nurses Week, which kicks off today, AHA and its American Organization of Nurse Executives subsidiary celebrate nurses for the invaluable role…
Insights and Analysis
Also in this weekly roundup of nursing news: A Florida nurse saves the life of a nearly drowned girl.
Insights and Analysis
Also in this weekly roundup of nursing news: a visiting nurse helps save a fallen man on the dance floor, and executive moves in the field.
Insights and Analysis
Also in this roundup of weekly nursing news: a North Carolina nurse calms her patients with song, and executive moves in the field.